Diabetics are regarded a special category of patients known to experience higher rates of cardiovascular complications as
compared to the non-diabetic ones. Despite substantial efforts to minimize these risks, with aggressive antiplatelet and lipid lowering
therapy, some of the diabetic patients still have a considerable residual risk for cardiovascular adverse events. Important preclinical data
with potent lipid-lowering agents, like fibrates, omega-3-fatty acids, and niacin, have shown that they can provide sufficient help in reducing
rates of cardiovascular events. In the present review, we are aim to explain their basic mechanisms of action, to present all the
available clinical data regarding the efficacy of those agents, and to identify specific diabetic patients’ subsets, in whom supplementary
therapy with those agents could provide substantial benefit in terms of clinical outcome and not only lipid profile improvement.
Keywords: Fibrates, omega 3, fish oil, niacin, myocardial infarction, stroke, statins, diabetes.
Rights & PermissionsPrintExport